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Summary: The lack of control of tumour behaviour is manifested in different ways, depending primarily on the
type of tumour. This results in numerous problems of tumour diagnosis and therapy. In the case of "benign"
tumours, like pituitary adenomas, in vitro studies are often used for evaluation of the tumour. The use of tissue
explant cultures of human pituitary adenomas and the comparison of the feature of cultured tumours with their
behaviour in vivo showed that corticotropin is released not only from the tumours associated with Gushing^ disease,
but also from clinically non-functioning tumours. Hence, it was supposed that the release of corticotropin in vivo
from non-secreting tumours is probably under the influence of certain neuroendocrine and/or systemic humoral
factors. To test this possibility, samples of 22 tumours were cultured in plain culture medium or in the presence
of the "human plasma ultrafiltrate bioactive fraction" (tentatively termed as TBP) prepared by anion-exchange
chromatography. In the presence of TBP the release of corticotropin was strongly inhibited in adenomas showing
relatively high spontaneous secreting activity in vitro (> 200 ng/1 in 24 hours), while immunohistochemistry of
these tumours indicated accumulation of corticotropin inside the cells. In contrast, TBP stimulated corticotropin
release from tumours that showed relatively low basic corticotropin release (< 200 ng/1 in 24 hours), with no
obvious change in cellular corticotropin immunoreactivity. Such a dual activity of TBP was not observed for 8
samples of adenomas cultured in the presence of surrounding pituitary tissue, probably because TBP did not affect
corticotropin secretion by the normal pituitary cells (as indicated by immunohistochemistry). From these results, it
appears that TBP could be one of the humoral factors involved in the regulation of corticotropin release from
pituitary adenoma tissue. Its possible involvement in the regulation of corticotropin release from normal pituitary
tissue, however, is uncertain.
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also unknown. Thus, tumours associated with clinical
evidence of hormone excess show high hormone secret-
ing activity if cultured in vitro, but clinically "non-func-
tioning" tumours also display a low level of hormone
secreting activity in vitro (4, 6). Most of clinically "non-
functioning" tumours, null cell adenomas and oncocyto-
mas secret follitropin and lutropin in vitro, but occa-
sional tumours (like normal pituitary gland) release so-
matotropin, prolactin and corticotropin, as well (6).
Similarly, we have noticed that in pituitary adenomas
cultured in vitro for 24 hours as tissue explant cultures
(intact samples of the tumourous tissue), the release of
corticotropin does not correspond to the hormonal activ-
ity of the tumours in vivo (11).
Hence, it seems that the secretory activity of pituitary tu-
mours may be influenced by systemic regulatory mecha-
nisms, probably mediated by hypothalamic as well as by
certain humoral factors. To test this possibility and to fur-
ther evaluate the hormone secreting activity of pituitary
tumours, their sensitivity to the "bioactive fraction of the
human plasma ultrafiltrate", tentatively termed as TBP1),
(12) was analysed in vitro.
Materials and Methods
Patients
Pituitary adenomas of 22 patients were analysed (tab. 1). Eleven
patients (5 male and 6 female) 25-76 (52 ± 18) years old had
clinically non-functioning tumours. All of them had visual distur-
bances and headaches, and preoperative CT imaging scans demon-
strated a macroadenoma. Basal serum levels of hormones were in
the reference range, except prolactin which was elevated in 5 pa-
tients (60.7 ± 20.9 μg/l) due to the stalk compression.
Five female patients, 29-40 (30 ± 5) years old, presented with
the syndrome of galactorrhoea and amenorrhoea associated with
elevated serum prolactin levels (185.2 ± 59.1 μg/l). Three men,
28-57 (42 ± 14) years of age, also had elevated serum prolactin
levels (274.1 ± 36.4 μg/l). In these two groups of patients the se-
rum corticotropin concentrations were not elevated. However, the
corticotropin values were increased in the sera of 2 patients with
manifested Cushing's disease (one male and one female, 31 and
66 years old respectively).
All the patients underwent pituitary operation, and subsequent mor-
phological evaluation of the tumours revealed 10 null-cell adeno-
mas, 8 sparsely granulated "prolactin cell" adenomas, two cortico-
tropin cell adenomas, one oncocytoma and one mixed densely
granulated somatotropin- and sparsely granulated prolactin-cell ad-
enoma. Samples of the tumours were cultured in vitro, and later
analysis showed that 8 of them contained pituitary gland tissue,
while the remaining 14 adenomas showed no indication of the pres-
ence of pituitary gland.
Hormone assay
Corticotropin was determined in sera and culture media by IRMA,
using the kit of CIS bio international (France). Coefficients of vari-
ation were below 10% and the detection limit for corticotropin was
2 ng/1 (reference plasma values were 10-75 ng/1). Background val-
ues of corticotropin determined for the plain culture media used as
a control were < 2 ng/1.
TBP = Tumour Basic Protein
Morphological studies
A portion of surgically removed pituitary adenoma was fixed in 40
g/1 buffered paraformaldehyde, dehydrated in graded ethanol, and
embedded in paraffin. An identical fixation procedure was applied
to the adenoma explants obtained after surgical removal of the tu-
mour, which were also used for the in vitro studies. Paraffin sec-
tions of 4 to 6 μηι thickness were stained with hematoxylineosin,
Mallory 3-chrome and the periodic acid-Schijff technique. For the
immunohistochemical detection of the pituitary hormones, the im-
munoperoxidase technique was used. Antisera for the following
hormones were used: thyrotropin (diluted 1 :500), prolactin
(1 :300), corticotropin (1 :400), somatotropin (1:500), follitropin
(1:150) and lutropin (1:700) (all by DAKO (Danmark)). Normal
pituitary tissue obtained at the autopsy served as positive control.
The specificity of each primary antiserum was previously verified
by adsorption with its respective primary antigen. For the electron
microscopic study, the portion of the adenoma tissue was fixed
in buffered 40 g/i paraformaldehyde, processed in buffered 20 g/1
osmium tetroxide, then embedded in Epon 812. Semithin sections,
stained with toluidine blue, were examined to select the areas ap-
propriate for the ultrastructural study. The ultrathin sections of 15
nm stained with uranyl-acetate and lead-citrate, were studied in an
Opton-Zeiss electron microscope EM 9S-2.
Preparation of the bioactive fraction of the human
plasma ultrafiltrate
For the preparation of the bioactive fraction of the human plasma
ultrafiltrate (tentatively termed as TBP!)) the pooled EDTA-
plasma of 49 healthy, male (20-35 years old) blood donors
(hepatitis and HIV negative) was used. A sample of 1 1 was
repeatedly filtered on an Amicon membrane ultrafiltration system
using a 30000 MT cut-off membrane (Amicon, Ireland) under
nitrogen pressure, in a stirred ultrafiltration cell. The eluant was
further repeatedly applied to the same ultrafiltration system using
a 3000 Λ/Γ cut-off membrane. The final retentate of 50 ml volume
was lyophilised and 5 mg of the lyophilisate was used for further
purification by anion exchange fast protein liquid chromatogra-
phy (FPLC). Anion-exchange chromatography was performed on
FPLC, Mod. LCC 500 (Pharmacia, Sweden) using a 1 ml Re-
source-Q-column (Pharmacia, Sweden) equilibrated with 10
mmol/1 Tris-buffer (pH 8.0).
Lyophilised 3000-30000 MT plasma ultrafiltrate was dissolved in
water (5 mg powder per 0.5 ml Tris H2O) and applied to the col-
umn. Column elution was started with 5 ml of Tris-buffer, followed
by a salt gradient of 0.5 ml NaCl in the same buffer within 30 min,
increasing finally to 1 mol/l NaCl in 5 min (chromatogram in figure
1). Two ml of fractions were collected and biological activity of
all the fractions was tested in vitro. According to its "immunomo-
dulating" activity for cultured human lymphocytes (12), a particu-
lar fraction (No. 9-TBP; eluted after 12 ml) was chosen for further
analysis. This was lyophilised and kept at + 4 °C. Further analyses
of TBP composition (fig. 2) using SMART Mini-Q anion-ex-
changer sepharose (Pharmacia, Sweden) revealed that TBP behaves
as a "double-peak" compound with a dominating sharp peak elut-
ing at approximately 35% of solvent B (10 mmol/1 Tris/HCl + 250
mmol/1 NaCl). Due to lack of material, further purification and
analysis of TBP have not yet been possible.
For experimental purposes the sample of TBP was dissolved in
saline, filtered through a 500 Mr cut-off membrane using saline as
elution liquid. The retentate was passed through a 0.22 μηι filter
(Millipore, USA) and aliquots were kept at -20 0C, until used in
vitro at a concentration of 100 g/I plasma equivalent concentration
(approximately 5 μg/l).
Adenoma tissue explant cultures
Pituitary adenoma tissue was collected in iced saline with penicillin
and streptomycin at the time of operation and washed twice with
the same solution. Afterwards, the weight of the wet tissue was
measured under sterile conditions, and the specimen was dissected
into equal pieces of approximately 4-6 mm3 size. The weight of
the tissue particles was measured again and the samples were
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Tab. 1 Characteristics of patients and pituitary adenoma tissue explants used for in vitro analysis.
Patient -
sex/age
1. ?/65
2. <J/65
3. ?/65
4. ?/28
5. <J/28
6. ?/38
7. ?/28
8. ?/70
9. ?/37
10. ?/25
11. c?/33
12. ?/70
13. <J/76
14. ?/51
15. ?/31
16. <J/57
17. cJ/41
18. <J/37
19. cJ/41
20. <?/66
21. ?/40
22. ?/28
Clinical findings
of adenoma
secretory activity
non-functioning
non-functioning
prolactinoma
prolactinoma
prolactinoma
non-functioning
prolactinoma
non-functioning
acromegaly
non-functioning
non-functioning
non-functioning
non-functioning
non-functioning
Cushing's disease
prolactinoma
prolactinoma
non-functioning
non-functioning
Cushing's disease
prolactinoma
prolactinoma
Pathological diagnosis of the
operated tumour specimen
null-cell adenoma
null-cell adenoma
sparsely granulated prolactinoma
sparsely granulated prolactinoma
sparsely granulated prolactinoma
null-cell adenoma
sparsely granulated prolactinoma
null-cell adenoma
mixed densely granulated somatotropin
cell adenoma and sparsely granulated
prolactinoma
null-cell adenoma
null-cell adenoma
null-cell adenoma
oncocytoma
null-cell adenoma
corticotropin-cell adenoma associated
with Gushing 's disease
sparsely granulated prolactinoma
sparsely granulated prolactinoma
null-cell adenoma
null-cell adenoma
corticotropin cell adenoma associated
with Cushing's disease
sparsely granulated prolactinoma
sparsely granulated prolactinoma
Serum
corticotropin
(ng/1)
12.2
8.5
12.3
22.5
19.9
9.9
12.9
16.3
1.5
16.5
24.8
28.1
1.5
0.6
228.6
27.6
7.0
11.3
22.1
221.0
17.4
31.7
Morphology
of tissue explant cultures*
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
chromophobic adenoma
oncocytoma
chromophobic adenoma
chromophobic adenoma
mixed with pituitary gland
chromophobic adenoma
mixed with pituitary gland
chromophobic adenoma
mixed with pituitary gland
chromophobic adenoma
mixed with pituitary gland
chromophobic adenoma mixed
with pituitary gland
chromophobic adenoma mixed
with pituitary gland
chromophobic adenoma mixed
with pituitary gland
chromophobic adenoma mixed
with pituitary gland
* — there were no major differences of the tissue morphology observed between the experimental and
the respective control adenoma tissue explant cultures
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Fig. 1 Preparative anion-exchange liquid chromatography of the
human plasma 3000-30000 MT membrane ultrafiltrate. Lyophili-
sed 3000-30000 Mr. plasma ultrafiltrate was dissolved in water
(5 mg powder/0.5 ml tris H2O-solvent A), applied to the column
and eluted with 5 ml of Tris-buffer followed 'by a salt gradient of
0.5 ml NaCl in the same buffer (solvent B = solvent A + 1 mol/1
NaCl) within 30 min, finally increasing to 1 mol/1 NaCl in 5 min.
* — Bioactive fraction (No. 9) used for the in vitro experiments;
tentatively termed as TBP.
placed in plastic Petri dishes (Greiner, Germany) containing Dul-
becco's Modified Eagle's Medium Ham's F-12 supplemented with
fetal calf serum (volume fraction 0.1) and 1 mU/l penicillin and
1 mg/1 streptomycin. The culture medium of the tissue explant cul-
tures treated with TBP contained the sample of bioactive plasma
ultrafiltrate fraction at 100 g/1 plasma equivalent. The volume of
the medium used for tissue explant cultures depended on the
weight of adenoma tissue, thus the ratio was 2 ml medium per
10 mg tissue. Tissue explants were first incubated at 37 °C in hu-
midified air containing 5% COi for 1 hour without any treatment
(for the comparison of the basic hormone secreting activity which
appeared to be equal for equivalent samples of the same tumour)
and then for 24 hours in the plain medium or in the medium con-
taining TBP.
Afterwards, the medium was removed and stored at -20 °C until
radioimmunoassay, while the tissue was fixed for morphological
analysis as described. Simultaneously, the same amount of medium
was incubated in the same way without any pituitary tissue, for
determination of the corticotropin background.
Statistics
Differences between the absolute values of corticotropin deter-
mined in the culture media of the control and TBP incubated
adenoma tissue explants were evaluated by the Mann-Whitney-
U test. Modulation by TBP of the corticotropin secretory activity
of the pituitary adenomas in relation to their basic hormone
secretory activity was evaluated using the Spearman rank corre-
lation.
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Results
The values of corticotropin found in the culture media
of adenomas that were surgically removed without pitu-
itary gland tissue (as revealed by histology, tab. 1) then
incubated in the plain medium or in the medium con-
taining TBP are presented in figure 3 and in table 2. If
the hormone values determined for the control media
were relatively high (> 200 ng/1), addition of TBP to
die culture medium resulted in a strong decrease of cor-
0.01 τ -r i.oo
GO
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Elution volume [ml]
Fig. 2 Analytical anion-exchange liquid chromatography of the
bioactive fraction of human plasma 3000—30 000 MT membrane ul-
trafiltrate.
Lyophilised TBP (amount corresponding to approximately 50 ml
of plasma) was dissolved in 25 μΐ of 10 mmol/1 Tris/HCl buffer
(pH 8) - solvent A, diluted 1 : 10 by H2O and applied to SMART
Mini-Q anion-exchanger Sepharose using a linear 250 mmol/1 NaCl
gradient in the same buffer (solvent Β = solvent A + 250
mmol/1 NaCl).
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Fig. 3 The effects of TBP on corticotropin release in vitro from
the pituitary adenomas incubated as tissue explants without pitu-
itary gland tissue.
Effects of TBP (shaded bars) on corticotropin release in the culture
medium (ng/1 · d) are presented in comparison with the respective
adenoma incubated in the plain medium only (opened bars).
* - patient number (according to the tab. 1) and clinical diagnosis
of the respective adenoma secretory activity; NF - non-function-
ing, P - prolactinoma, A - acromegaly.
ticotropin concentration (P = 0.0008). In contrast, if the
tumours showed a lower capacity for corticotropin
secretion in vitro (< 200 ng/1), addition of TBP
increased their corticotropin secreting activity
(P = 0.0283). Thus, for the in vitro high corticotropin
secreting adenomas the inhibition fof the hormone re-
lease ranged from 47-99%, while the stimulated hor-
mone release observed for the low corticotropin secret-
ing tumours was 162—2370% of the respective basic
control hormone secreting activity. Furthermore, while
immunohistochemistry of the control "high corticotropin
secreting" tumours revealed weak corticotropin positi-
vity in only one adenoma tissue explant culture, cortico-
tropin positivity was observed for almost all those ade-
noma explants incubated with TBP, for which inhibition
of the corticotropin in the culture medium was noticed.
Such effects of TBP on the corticotropin secreting activ-
ity of the pituitary tumours in vitro were observed only
for those tumours removed by surgery without pituitary
gland tissue. If the samples of tissue explant cultures
contained pituitary gland tissue in addition to adenoma-
tous tissue (as revealed by histology, tab. 1) (fig. 4 and
tab. 3), addition of TBP1) did not produce any regular
and significant effect P > 0.1). Although high cortico-
tropin concentrations (> 200 ng/1) were measured in the
medium of all these cultures, a moderate decrease (ap-
proximately 50% or less) of the corticotropin concentra-
tion in the culture medium was noticed for three tissue
explant cultures only. Moreover, for two other samples
of this group TBP was even stimulatory (above 250%
of the respective control value), in spite of the high cor-
ticotropin concentrations in the control culture medium.
Immunohistochemistry of the control tissue explant cul-
tures showed moderate to strong corticotropin positivity
in four tumours. For all of these, addition of TBP to the
culture medium decreased corticotropin positivity in the
tumour cells, although there was no obvious change of
the hormone concentration in the culture medium. Wide-
spread corticotropin staining of the normal pituitary tis-
sue was noticed in all the tissue explants, in the control
samples, and in the TBP treated tissue explants.
Furthermore, there was a strong negative correlation
(r = -0.92, P < 0.01) between the dependence of the
biomodulating effects of TBP on the corticotropin secre-
tory activity of the pituitary adenomas and their basic
hormone secretory activity (fig. 5); such a correlation
was not observed for the samples of pituitary adenomas
incubated with the pituitary gland tissue (r = -0.14,
P > 0.1). Thus, while TBP did not influence corticotro-
pin release from the tissue explant cultures of the
tumours mixed with the pituitary gland tissue, the dual
effect of TBP on corticotropin secretion in vitro, i. e.
inhibition of the secreting activity of "high corticotro-
pin secreting" tumours and stimulation of corticotropin
secretion of "low corticotropin secreting" tumours was
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Tab. 2 Comparison of the corticotropin secretory activity and immunohistochemistry
(corticotropin positivity) of the pituitary adenoma explants without normal pituitary gland tissue.
Patient -
sex/age
1. 9/65
2. ί/65
3. 9/27
4. 9/28
5. <f/28
6. ?/38
7. ?/28
8. ?/70
9. 9/37
10. 9/25
11. <ί/33
12. ?/70
13. c?/76
14. ?/51
Clinical findings
of adenoma
secretory activity
non- functioning
non-functioning
prolactinoma
prolactinoma
prolactinoma
non-functioning
prolactinoma
non-functioning
acromegaly
non- functioning
non-functioning
non:functioning
non-functioning
non-functioning
Control
adenoma
tissue explant
culture cortico-
tropin secretory
activity (ng/1)
9500.0
4619.0
3000.0
1698.0
857.0
761.0
498.3
308.0
226.6
127.7
62.1
42.8
22.8
16.5
Relative values of
adenoma tissue
explant culture
corticotropin
secretory activity
in presence of TBP
(% of the respective
control value)
0.5
2.9
2.6
3.4
13.2
31.3
5.9
29.2
52.3
548.1
162.2
324.8
409.7
2369.7
Immuno-
histochemistry
(corticotropin
positivity) of the
adenoma cells in the
control adenoma
tissue explant
cultures
negative*
negative
+
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
Immuno-
histochemistry
(corticotropin
positivity) of the
adenoma cells in the
tissue explants
cultured in presence
of TBP
+
+ + +
+ +
+
+ +
+ +
negative
negative
not done
negative
negative
negative
netative
not done
negative no positive cells
weak positivity (< 5% of the cells)
moderate staining (approximately 25% of the
cells)
strong staining (50-75% of the cells)
According to Katznelson et al. (13) tissue explants were cultured
for 24 hours in the plain medium (control) or in the medium con-
taining bioactive fraction (100 g/1 plasma equivalent concentration)
of the human plasma ultrafiltrate (TBP).
strong and regular, provided the adenoma tissue was
removed without traces of the surrounding pituitary
gland.
Discussion
The results obtained show that the human plasma ultra-
filtrate bioactive fraction (TBP) contains potent factor(s)
which regulate(s) secretion of corticotropin from the hu-
man pituitary adenoma tissue explants in vitro. The na-
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Fig. 4 The effects of TBP on corticotropin release in vitro from
the pituitary adenomas incubated as tissue explants in the presence
of pituitary gland tissue.
Effects of TBP (shaded bars) on corticotropin release in the culture
medium (ng/1 · d) are presented in comparison with the respective
adenoma incubated in the plain medium only (opened bars).
* - patient number (according to the tab. 1) and clinical diagnosis
of the respective adnoma secretory activity; NF — non-functioning,
P - prolactinoma; C — Cushing's disease.
ture of the active component of TBP is not yet defined.
However, it might be similar to the growth modifying
factor found as a heat and acid resistant component in
different tissues and culture media (12, 14, 15). Similar
factors modifying tumour cell behaviour have been de-
scribed under various names (depending on the source
of preparation, method of purification and the bioassay
used for determination of the activity) (16—21). The ba-
sic principle of the biological activity of TBP is still
uncertain, but it appears to be a ubiquitous factor that
modifies cellular activity. Due to its ability to pass
through a Mr 30 000 cut-off membrane and inability to
pass through a MT 3000 cut-off membrane, the Mr of
TBP should be within the range of numerous bioactive
peptides and low Μτ proteins (20, 22). TBP cannot be a
non-specific very low Mr component (like hydrocorti-
sone, cAMP, etc.) since the MT of such factors is below
3000. Thus it is not yet known, whether TBP is a new
bioactive plasma (and/or tissue) factor. Preliminary data
indicate that TBP could also influence the reactivity of
the human peripheral blood mononuclear cells to phyto-
haemagglutinin, stimulating the reactivity of poorly re-
active cells and inhibiting the reactivity of highly re-
active cells (12).
Similarly, the results show that the effects of TBP on
corticotropin release from the cultured pituitary adeno-
mas depended on the basal corticotropin secreting activ-
ity of the adenomas. Thus, TBP inhibited (on average
more than 90%) corticotropin release from the adeno-
mas that exerted relatively high basic hormone release
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(200 ng/1 in 24 hours appeared to be the minimal re-
leased control corticotropin value which was inhibited).
In contrast, TBP stimulated corticotropin release (on
average up to four-fold) by the adenomas that exerted
relatively low (< 200 ng/1 in 24 hours) basic hormone
release. Furthermore, almost opposite results were ob-
tained for corticotropin immunohistochemistry and cor-
ticotropin concentration in the medium of the control
and TBP treated "high corticotropin secreting" adeno-
mas, indicating that TBP inhibition was actually pre-
vented of the release of the hormone into the culture me-
dium.
In tissue explant cultures of the "low corticotropin
secreting" tumours, increase of corticotropin concentra-
tion in the culture medium was not associated with any
obvious change of the cellular corticotropin immunore-
activity. Hence, either the TBP activity mechanism was
different for the high and for the low corticotropin secre-^
ting (or releasing) adenomas, or immunohistochemistry
could not reveal corticotropin in the "low corticotropin
secreting" tumours.
Corticotropin in TBP cultures,
percent of control
Fig. 5 Dependence of the effects of TBP on the corticotropin se-
cretory activity of the cultured pituitary adenomas in relation to
their basic cortieotropin secretion in vitro.
A - samples of the pituitary adenomas cultured without pituitary
gland; B - samples of the pituitary adenomas cultured with sur-
rounding pituitary gland tissue.
The relative effects of TBP (expressed .as percentage of the hor-,
monal activity measured for the same'tumours incubated in the
plain culture medium) were compared by using the Spearman
rank correlation.
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Such effects of TBP were not observed if the adenoma
samples contained pituitary gland tissue. That was a sur-
prising finding, since most of these samples showed a
very high basic corticotropin secretion, so that a rela-
tively strong inhibition by TBP could be expected. There
are at least two possible explanations for this ineffec-
tiveness of TBP. Thus, either TBP could not suppress
corticotropin release from the pituitary gland in these
tissue explant cultures, or it could not suppress cortico-
tropin release from the adenoma tissue, due to interfer-
ence by the tumour and pituitary gland corticotropin
secretion.
In favour of the first possibility is the presence of high
corticotropin in the culture media of the normal pituitary
gland (23) and widespread immunohistochemical positi-
vity to corticotropin in the normal pituitary surrounding
adenoma tissue, which was not influenced by TBP treat-
ment. The finding of decreased immunohistochemical
positivity of the tumour cells after treatment with TBP,
with no effect on corticotropin concentration in the cul-
ture medium of the adenomas incubated with the sur-
rounding pituitary gland, could indicate that TBP has a
different effect on normal pituitary and adenoma cells,
i. e. stimulating the release of corticotropin from the tu-
mour cells, but not affecting corticotropin metabolism
in the normal cells. However, this possibility should be
verified by further experimental studies.
The second possibility cannot be excluded, since it was
not possible to distinguish release of corticotropin from
the adenoma and corticotropin release from the sur-
rounding pituitary gland tissue. Moreover, cell to cell
communication is of high importance in the regulation
of corticotropin secretion (24), and the integrity of the
tumourous and surrounding pituitary tissue was pre-
served during incubation of these tissue explants.
On the other hand, it is possible that TBP influenced
the hormonal activity of "multipotential pituitary cells"
which mainly contain corticotropin and play an impor-
tant role in the regulation of hormone secretion by the
other pituitary cells (25).
Furthermore, post-surgical stress (removal of the pitu-
itary tumour) as well as growth factor synthesis by the
tumourous tissue in vitro modulate hormone secretion
(26-28). It is possible that TBP (bioactive fraction of
the human plasma ultrafiltrate) contains factor(s) in-
volved in the stress reaction or paracrine regulation of
the growth factor synthesis, thus indirectly affecting the
hormone release, but these possibilities have to be fur-
ther evaluated. Finally, it is not impossible that TBP, like
some other bioactive peptides (29-35), is involved in
regulation of adenylate cyclase activity and/or calcium
metabolism, thereby acting as a regulator of the hor-
monal activity of the normal and tumourous pituitary tis-
sue.
From the present results, however, it seems that TBP
could be the humoral factor involved in the regulation
corticotropin release from the pituitary adenoma tissue,
but not in the regulation of corticotropin release from
normal pituitary tissue. To verify this possibility, it
will be necessary not only to analyse the nature of
this bioactive component of the human plasma ultrafil-
trate but also to use the advantages of the tissue
explant culture method to evaluate the effects of TBP
on the hormone release from the normal pituitary
gland, as well as on the growth features of normal
and tumour cells.
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